This Week in Cardiology Jun 27 2025 This Week in Cardiology
4 snips
Jun 27, 2025 Discover groundbreaking news as the FDA approves a triple-drug polypill for hypertension, igniting discussions on its pros and cons. Explore evolving views on managing hypertension, especially in elderly patients. Dive into innovative invasive therapies for pulmonary embolism, revealing both techniques and knowledge gaps. Heart disease trends and the increasing urgency of diabetes care are also highlighted, showcasing the latest in cardiology. Tune in for expert insights and a blend of humor on these vital health topics!
AI Snips
Chapters
Transcript
Episode notes
Polypill Simplifies Hypertension Care
- The newly FDA-approved triple-drug polypill simplifies hypertension treatment with three combined medications.
- Early success with a single pill improves adherence and patient confidence more than multiple prescriptions.
Working with Tom Tu on PE Therapy
- John Mandrola shares his close work with his former partner Tom Tu on interventional cardiology and debates.
- Grew interest in invasive pulmonary embolism therapies sparked by impressive catheter clot removal visuals.
PE Devices Lack Robust Evidence
- Many FDA-approved PE devices lack strong evidence but gained authorization via similarity to prior devices.
- Endovascular PE therapies show uncertain benefit, with ongoing trials hindered by strict criteria and potential bias from financial incentives.